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Crystallization of recombinant proteins has been funda-
mental to our understanding of protein function, dysfunc-
tion, and molecular recognition. However, this information
has often been gleaned under extremely nonphysiological
protein, salt, and H concentrations. Here, we describe the
development of a robust Inka1-Box (iBox)–PAK4cat system
that spontaneously crystallizes in several mammalian cell
types. The semi-quantitative assay described here allows the
measurement of in vivo protein-protein interactions using a
novel GFP-linked reporter system that produces fluorescent
readouts from protein crystals. We combined this assay with
in vitro X-ray crystallography and molecular dynamics
studies to characterize the molecular determinants of the
interaction between the PDZ2 domain of Na/H exchange
regulatory cofactor NHE-RF1 (NHERF1) and cystic fibrosis
transmembrane conductance regulator (CFTR), a protein
complex pertinent to the genetic disease cystic fibrosis. These
experiments revealed the crystal structure of the extended
PDZ domain of NHERF1 and indicated, contrary to what has
been previously reported, that residue selection at positions
1 and 3 of the PDZ-binding motif influences the affinity
and specificity of the NHERF1 PDZ2-CFTR interaction. Our
results suggest that this system could be utilized to screen
additional protein-protein interactions, provided they can be
accommodated within the spacious iBox-PAK4cat lattice.
The catalytic domain of the serine/threonine kinase PAK4
(PAK4cat)3 and its endogenous inhibitor Inka1 have recently
been shown to readily form rod-type crystals on co-transfection
into a variety of mammalian cell types (1). Crystals formed fol-
lowing transfection of a fusion construct comprised of a central
38-residue region of Inka1, termed the Inka1-Box (iBox), and
PAK4cat (iBox-PAK4cat) were diffracted at the synchrotron
beamline, enabling the first in cellulo human protein structure
to be determined to 2.95 Å (PDB 4XBR). The crystal lattice
revealed that iBox-PAK4cat forms a hexagonal arraywith chan-
nels 80 Å in diameter that run the length of the crystal. The size
of this cavity allowed a guest protein (GFP) to be incorporated
into the crystal lattice (1). This, as well as the relative ease with
which crystals can be generated following transfection of DNA
intomammalian cells, suggests that iBox-PAK4cat crystalsmay
be a useful tool for a variety of experimental purposes, including
crystallization of guest proteins, use as environmentally re-
sponsive cellular sensors, and use in protein-protein interac-
tion (PPI) screening assays.However, the potential uses of iBox-
PAK4cat in cellulo crystals for both structural and other
applications, are relatively unexplored and require further
study.
PSD-95/Dlg-1/ZO-1 (PDZ) domains constitute one of the
most commonly identified protein interaction modules, with
over 500 PDZ domain-containing proteins identified in the
human genome alone (2). PDZ domains characterized to date
share a common core structure, consisting of a 6-stranded
antiparallel  sandwich structure (1–6) flanked by an helix
on each side (1,2). PDZdomains fulfil their scaffolding func-
tion through the recognition of short linear PDZ-binding
motifs that are commonly found at the extreme C termini of
receptors and ion channels. It is generally agreed that PDZ-
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binding motifs are comprised of four residues, referred to by
convention as P0, P-1, P-2, and P-3 from theC-terminal residue
inward. Early studies characterizing PDZ domain-motif inter-
actions led to the classification of PDZ domains based on their
preferences for particular PDZ-bindingmotifs, indicatingmotif
selection is primarily dictated by the motif residues at P0 and
P-2. Peptide library screening studies identified PDZ domains
that displayed distinct preferences for the type I motif X-(S/T)-
X- (where is a hydrophobic amino acid and X is any amino
acid), the type II motif X--X- (3, 4), or the less common type
III motif X-(D/E)-X- (5).
The cystic fibrosis transmembrane conductance regulator
(CFTR), or ABCC7, is a chloride ion channel expressed in the
epithelia of the airways, intestine, pancreas, sweat gland, and
testis (6). Loss-of-function mutations of CFTR cause the auto-
somal-recessive disease cystic fibrosis (CF). CF is the most
prevalent genetic disease among European populations, affect-
ing on average 1 in every 3500 live births (7). Themost common
CF-causing mutation is the deletion of phenylalanine at posi-
tion 508 (F508del), which is present on at least one allele in 90%
of patients in some populations (8). The F508del mutation
causes protein misfolding and subsequent targeting of CFTR
for degradation via the endoplasmic reticulum-associated deg-
radation pathway (9). CFTR contains the conserved type I PDZ-
binding motif (D/E)T(R/K)L at its C terminus. Through this
motif, CFTR is known to interact with several PDZ domain-
containing proteins, including CFTR-associated ligand (CAL),
Shank2, as well as all four members of the NHERF family
(NHERF1, NHERF2, NHERF3, and NHERF4) (10–13).
NHERF1 is comprised of two PDZ domains (PDZ1 and PDZ2),
both of which are able to bind to the PDZ-binding motif of
CFTR (10, 14–17). NHERF1 has been shown to increase both
the activity and plasmamembrane localization of bothWT and
F508del CFTR (18–23). Although mutations of the CFTR C
terminus are rare, they have been reported as being disease-
causing (24). Furthermore, CFTR variants in which the CFTR
PDZ-binding motif is compromised through either truncation
or substitution (e.g. S1455X, Q1476X, and L1480P) have been
associated with various CF-related disorders such as elevated
sweat chloride concentration and congenital bilateral absence
of the vas deferens (see RRID:SCR_000685). It has been dem-
onstrated that whereas F508del CFTR interacts poorly with
NHERF1, the CFTR corrector VX-809 increases the binding
affinity between these two proteins (25). Together, these stud-
ies suggest that one potential strategy for the further develop-
ment of CF therapeutics may be the generation of small mole-
cule corrector-type drugs specifically targeted at enhancing the
interaction between NHERF1 and CFTR. Indeed, more gener-
ally, there is significant interest in targeting specific PDZ
domain-motif interactions with small molecule inhibitors or
peptides that block the PDZ-binding site (26, 27). The develop-
ment of drugs that target certain PDZ domains but not others,
however, remains challenging and requires further character-
ization of the molecular determinants of specific PDZ domain-
motif interactions.
The experiments described here employ a variety of ap-
proaches to further characterize themolecular determinants of
the interaction between the second PDZ domain of NHERF1
and the CFTR. These results indicate that the PDZ-binding
motif of CFTR appears to be an optimal PDZ-binding motif for
interactionwith PDZ2ofNHERF1, and that residue selection at
the1 and3 motif positions appears to influence the affinity
and specificity of the interaction. These findings have been cor-
roborated in cellulo through the development of a novel PPI
screening assay based on the iBox-PAK4cat crystallization sys-
tem. This study demonstrates that iBox-PAK4cat crystals rep-
resent a potentially useful tool for the study of PDZ domain-
motif interactions in a cellular context and may be a useful tool
in future screening studies.
Results
The structure of the extended NHERF1 PDZ2 domain
To understand fully the determinants of the NHERF1
PDZ2-CFTR interaction we sought to determine the co-
crystal structure. To facilitate co-crystallization, a chimeric
construct was generated in which the NHERF1 PDZ2
domain (NHERF1 residues 150–270) was fused to a C-ter-
minal DTRL tetrapeptide motif corresponding to the last
four residues of CFTR (CFTR residues 1477–1480), mirror-
ing an approach commonly used for crystallization of PDZ
domain-motif complexes (28–31). This strategy produced
diffraction-quality crystals, enabling the structure to be
solved and refined to 2.2 Å (Table 1).
The overall topology of the canonical NHERF1 PDZ2
domain is consistent with standard PDZ domains, compris-
ing of a 6-stranded -barrel (1–6) and two -helices (1
and 2) (Fig. 1A). In agreement with previous reports (17),
the structure revealed that NHERF1 PDZ2 contains addi-
tional structured extensions beyond the core PDZ-fold.
These extended regions form an - (3) and a 310 (4) helix,
which pack against the 1, 4, and 6 strands through the
formation of a closed hydrophobic cluster (Fig. 1B). Al-
though this hydrophobic cluster is formed from residues dis-
tal to the binding site, the extended NHERF1 PDZ2 domain
has been shown to have an almost 18-fold higher binding
affinity for the CFTR C terminus than the canonical domain
(17). Comparison of the structure of the extended NHERF1
PDZ2 with the canonical domain (NHERF1 residues 148–
239) in the apo form (PDB 2OZF) reveals high structural
similarity, with a RMSD of 0.74 Å for the 85 eq C atoms
(Fig. S1). This indicates that the extended region does not
induce significant structural changes in the core PDZ
domain, but rather conveys its effects through allosteric
interactions that mediate the stability of the binding site.
Interestingly, multiple sequence alignment and secondary
structure predictions indicate that similar structured exten-
sions outside of the core PDZ-fold are common to several
members of the NHERF family (Fig. 3B, Fig. S2), although
thus far only those of NHERF1 have been characterized.
The determinants of the NHERF1 PDZ2-CFTR interaction
The PDZ-binding motif of CFTR inserts into the 2–2
binding groove in a canonical fashion (Figs. 1A and 2A), extend-
ing the -sheet of the PDZ domain and burying a solvent-ac-
cessible surface area of 876 Å2. The DTRL peptide at the CFTR
C terminus represents a typical type I PDZ-binding motif, and
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as such, the structure presented here shares many common
features with a typical type I PDZ domain-motif interaction.
The T-2 residue of the PDZ-binding motif can be observed
to form a hydrogen bond with a conserved histidine residue
at position 212 of NHERF1 PDZ2 (Fig. 2A), consistent with a
shared mechanism of recognition found in type I interac-
tions. The L0 carboxyl group and leucine side chain appear
to be key determinants of binding through interactions with
the conserved 163GYGF167 carboxylate-binding motif and
hydrophobic binding pocket, respectively (Fig. 2). In partic-
ular, the binding pocket appears to be stereochemically
adapted to accommodate the leucine side chain (Fig. 2B).
Other residues of the PDZ-binding motif can be observed to
take part in numerous interactions with the NHERF1 PDZ2
domain. Specifically, the D-3 side chain forms a salt bridge
with Arg180 and a hydrogen bond with His169, and R-1 forms
a salt bridge with Asp183 and a hydrogen bond with Asn167
(Fig. 2A).
Several studies have indicated that the CFTR C terminus
binds to NHERF1 PDZ2 with lower affinity than PDZ1 (10, 17,
32). Indeed, whereas NHERF1 PDZ1 and PDZ2 domains share
54.4% sequence identity, they have been shown to display dis-
tinct differences with regards to ligand binding selectivity and
affinity. The PDZ domains of NHERF1 are highly structurally
similar (Fig. 3A). However, natural sequence variation of a
number of key residues within the binding pocket can be
observed, including the substitution of Glu-43 within PDZ1
with an aspartate residue at the equivalent position (Asp183)
within PDZ2 (Fig. 3B). Studies have suggested that the lower
binding affinity of PDZ2 can be attributed to the shorter side
chain of Asp183 that cannot form a salt bridge with the R-1
residue of the CFTR PDZ-binding motif (17, 33). The crystal
structure presented here contradicts this hypothesis, because
the salt bridge between Asp183 and R-1 is present (Figs. 2A and
3A). The majority of known CFTR-binding PDZ domains con-
tain a negatively charged residue at this position within the
binding pocket, including those outside of the NHERF family
such as Shank1 (Fig. 3B), implying that it is charge rather than
side chain length that is important. Furthermore, a positively
charged residue at P-1 of the PDZ-binding motif is conserved
cross-species for CFTR (Fig. S3). As such, these results indicate
that the formation of an ionic interaction between these two
residues may be a common mechanism for recognition and
selectivity between CFTR and its respective CFTR-binding
PDZ domains.
Use of iBox-PAK4cat in cellulo crystals as a tool for studying
protein-protein interactions
The in cellulo crystal structure of iBox-PAK4cat revealed a
hexagonal lattice with channels80 Å in diameter that run the
length of the crystal (1). We hypothesized that it may be possi-
ble to introduce NHERF1 PDZ2 into the crystal lattice to facil-
itate its in cellulo crystallization. A NHERF1 PDZ2 containing
iBox-PAK4cat fusion construct (iBox-PDZ2-PAK4cat) readily
formed diffraction-quality crystals (Fig. S4, Table S1). A partial
electron density map was revealed for the PDZ2 domain,
although it was of insufficient quality to trace the full polypep-
tide chain (Fig. S5), indicating that additional construct optimi-
zation is required to stabilize guest proteins in a single orienta-
tion within the crystal lattice. GFP-containing fluorescent
crystals have also been produced through co-transfection of
PAK4cat with various GFP-Inka1 constructs (1). In an exten-
sion of these approaches, we postulated that, throughmonitor-
ing of GFP fluorescence levels, iBox-PAK4cat crystals could
also be utilized as high-density in vivo sensors for the detection
of protein-protein interactions. In particular, we sought to uti-
lize the iBox-PAK4cat system as a tool to enable detection of
PDZ domain-motif interactions. This approach is summarized
in Fig. 4A. Two crystal-forming constructs were tested, one
containing a C-terminal tetrapeptide corresponding to the
CFTR PDZ-binding motif (iBox-PAK4cat-DTRL), and a nega-
tive control containing a non PDZ-binding C-terminal motif
(iBox-PAK4cat-AAAA). Although both iBox-PAK4cat-DTRL
and iBox-PAK4cat-AAAA constructs appeared to be similar in
terms of crystal generation proficiency (Fig. S6), iBox-
PAK4cat-DTRL crystals demonstrated clearly observable GFP
fluorescence on co-transfection with GFP-NHERF1PDZ1. Co-
transfection with iBox-PAK4cat-AAAA, however, resulted in
only cytoplasmic GFP fluorescence, with minimal fluorescence
observable in the crystals (Fig. 4B). The easily visible crystals
formed from GFP-NHERF1PDZ and iBox-PAK4cat-DTRL co-
transfection allowed for time-lapse analysis of crystal formation
(Movie S1).
iBox-PAK4cat in cellulo protein-protein interaction assay
reveals the determinants of NHERF1 PDZ domain binding
selectivity
Because iBox-PAK4cat crystals enable clear visual differ-
entiation between binding and nonbinding events on
co-transfection with GFP-PDZ (Fig. 4B), we sought to deter-
mine whether this system could also detect changes to the
Table 1
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PDZ-binding motif. A number of constructs were generated
in which residues of the CFTR PDZ-binding motif were
mutated to alanine, as well as a phosphomimetic motif in
which the threonine of the PDZ-binding motif was mutated
to glutamic acid (Fig. 5A). On co-transfection with GFP-PDZ
constructs, visual comparison indicated that these substitu-
tion mutants demonstrated lower levels of crystal fluores-
cence than the iBox-PAKcat-DTRL construct (Fig. 5B, Fig.
S7). In particular, introduction of the C-terminal leucine to
alanine substitution mutant (iBox-PAK4cat-DTRA) had a
drastic effect, with crystal fluorescence levels appearing sim-
ilar to the iBox-PAK4cat-AAAA negative control (Fig. 5B,
Fig. S7). That such a large effect comes from a relatively
conservative amino acid change may be understood by the
stereochemical adaptation of the binding pocket to leucine
observed in the crystal structure (Fig. 2B).
To characterize these constructs further, we sought to quan-
tify the intensity of GFP fluorescence within the crystals. To
remove background fluorescence caused by GFP-PDZ expres-
sion in the surrounding cells, crystal-containing cells were
lysed, and crystals were imaged in a cell-free form (Fig. S9). For
co-transfections employing iBox-PAK4cat-DTRA constructs,
Figure 1. The extended PDZ2 domain of NHERF1 in complex with the CFTR PDZ-binding motif. A, the extended helical regions (green) couple to the
canonical PDZ domain (purple) at a region distal to the PDZ-binding motif (teal). B, hydrophobic interactions formed between the 3 and 4 and 1, 4, and
6 from the core PDZ-fold.
Figure 2. Interactions between NHERF1 PDZ2 and CFTR. A, stereo view of the NHERF1 PDZ2-binding site (cyan) bound to the PDZ-binding motif of CFTR
(beige). The 2Fo  Fc map is shown around the CFTR PDZ-binding motif contoured at 1.0  within 1.5 Å of the selected atoms. B, hydrophobicity surface
structure of the NHERF1 PDZ2-binding site based on the Kyte-Doolittle scale with the most hydrophillic regions shown in blue and most hydrophobic regions
shown in orange-red. The CFTR PDZ-binding motif is shown as a stick model in beige. Image was generated using Chimera (60).
In vivo crystals reveal protein interactions
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levels of fluorescence were not above control levels. For the
remaining constructs, quantitative analysis indicated that
ATRL,DARL,DTAL, andDERLcontaining iBox-PAK4cat con-
structs demonstrated significantly lower levels of fluorescence
than that of iBox-PAK4cat-DTRL (Fig. 5C). As such, it is evi-
dent that all residues of the CFTR “DTRL” PDZ-binding
Figure 3. Comparison of human CFTR-binding PDZ domains. A, NHERF1 PDZ2-DTRL, NHERF1 PDZ1-DTRL (PDB 1I92), and overlay structures are shown as
indicated. NHERF1 PDZ2-DTRL is shown as previously. NHERF1 PDZ1 is shown in orange and the PDZ-binding motif of CFTR in green. In both cases side chain
groups of residues relevant to the ligand interaction are indicated. Black dashes represent bond distances measuring 3.3 Å or less. B, multiple sequence
alignment of known CFTR-binding PDZ domains. Residue numbers and secondary structure of NHERF1 PDZ2 are indicated above. Conserved “X--G-”
carboxylate-binding loop and key residues within the PDZ-binding pocket, including D183/E43, are boxed.
In vivo crystals reveal protein interactions
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motif form specific interactions within the binding pockets
of NHERF1 PDZ1 and PDZ2.
Molecular dynamics simulations and binding free energy
studies on NHERF1 PDZ2-CFTR complex
The crystal structure presented here, supported by the find-
ings of the novel iBox-PAK4cat in cellulo PPI assay, indicate
that side chain-mediated interactions within the NHERF1
PDZ2-binding pocket enable the specific recognition of the
CFTR PDZ-bindingmotif. To explore these findings further, in
silico, molecular dynamics (MD) simulations were performed.
Following evaluation and verification of the protonation
states of the histidine residues within the binding pocket
(“Experimental procedures,” Fig. S10), MD simulations were
carried out using the obtained NHERF1 PDZ2-DTRL crystal
structure. Simulations confirmed the persistence of hydrogen
bonds observed in the crystal structure. R-1 was found to
steadily form a salt bridge with the carboxylate of Asp183, as the
interactions between the carboxylic group of the D-3 with the
guanidine group of Arg180 and the side chain of His169. Simi-
larly, the interaction between the hydroxyl group of T-2 and the
side chain of His212 showed a clear occupancy for 83–85% of
the 50-ns production run. Two different binding modes could
be observed for the terminal carboxylate group of L0: the first,
similar to the initial structure and involving direct interaction
with the conserved GYGF carboxylate-binding motif; the sec-
ond, with the terminal carboxylate shifted and more inclined
toward Arg220 in the opposite direction (Fig. 6). Surprisingly, in
this mode, the initial direct interactions between the L0 termi-
nal carboxylate and the GYGF motif are mediated by a water
molecule that steadily occupies the space vacated by the car-
boxylate during its shift toward Arg220. This water molecule
forms a network of interactions involving L0 and the GYGF
motif when there are no direct interactions among the residues.
A shift in theR-1 side chain could also be observed, enabling the
interaction of the R-1 side chain with the backbone carbonyl of
Ser162 and a strong stabilization of the already present interac-
tion with the amidic carbonyl group of the Asn167 side chain.
This orientation of the R-1 side chain appears to be an interme-
diate between those observed in the PDZ1 and PDZ2 crystal
structures (Fig. 3A), and is coupled with L0 carboxylate shift
and tightening of the 1–2 loop (Fig. 6).
To confirm the findings of the iBox-PAK4cat protein-pro-
tein interaction assay, the same protocol was utilized to per-
form MD simulations on NHERF1 PDZ2 in complex with the
Figure 4. Use of iBox-PAK4cat in cellulo crystals as a tool for studying protein-protein interactions. A, schematic of the iBox-PAK4cat PPI assay. Mam-
malian cells are co-transfected with GFP-PDZ and iBox-PAK4cat constructs containing a C-terminal tetrapeptide motif (iBox-PAK4cat-DTRL and iBox-PAK4cat-
AAAA). For iBox-PAK4cat-AAAA no interaction takes place and GFP-PDZ is not incorporated into the iBox-PAK4cat crystal lattice. Conversely, for iBox-PAK4cat-
DTRL a PDZ domain-motif interaction occurs and GFP-PDZ is incorporated into the iBox-PAK4cat crystal lattice. The iBox-PAK4cat (red and teal, respectively) in
cellulo crystal structure (PDB 4XBR) bound to GFP-PDZ (green and blue, respectively) is modeled for illustrative purposes only. B, fluorescent images of cells
co-transfected with GFP-NHERF1 PDZ1 and iBox-PAK4cat-DTRL or iBox-PAK4cat-AAAA, as indicated. Equivalent transmitted light images are shown in Fig. S6.
Scale bar bottom right indicates 100m.
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ATRL, DARL, DTAL, and DTRA alanine substitution mutants
of the PDZ-binding motif. For these simulations, the RMSD
values related to the secondary structure elements were found
to remain in the same range as for the WT complex. However,
the stability of the peptide for all alanine substitution mutants
was found to be much lower (Fig. S11), presumably due to the
absence of key interactions within the binding pocket. To
determine the effect of these mutations on interaction affinity,
binding free energies for both replicates were calculated using
both the solvation interaction energies (SIE) and molecu-
lar mechanics Poisson-Boltzmann surface area (MM-PBSA)
methods (Table 2). During the initial evaluation of different
protonation states on theWT simulations, the estimated bind-
ing energies were all found to be in agreement using bothmeth-
ods. However, with theMM-PBSAmethod only the ATRL and
the DTAL systems were found to be substantially less favorable
in terms of binding energies, whereas using the SIE method,
and in agreement with the findings of the iBox-PAK4cat PPI
assay, all alanine substitution mutants were found to be less
energetically favorable than the WT motif. In particular, the
presence of the guanidino group at P-1 appears to be critical to
the formation of interactions within the binding pocket, with a
decrease over 4 kcal/mol (SIE method) and 15 kcal/mol (MM-
PBSA) observable for both replicas of the DTAL system.
Discussion
The findings presented here corroborate published data,
which indicate that NHERF1 PDZ2 contains structured exten-
sions outside of the core PDZ-fold (16, 17). Structured exten-
sions outside of the canonical PDZ domain are not unique to
NHERF1 PDZ2. NHERF1 PDZ1 has been shown to contain a
highly similar C-terminal helical region, albeit with only com-
paratively negligible effects on stability and ligand binding
affinity (17). The results presented here indicate that similar
Figure 5. Effect of PDZ-binding motif mutations on GFP integration into iBox-PAK4cat crystals. A, iBox-PAK4cat constructs utilized in this study. B,
fluorescent images of cells co-transfected with GFP-NHERF1 PDZ2 and iBox-PAK4cat constructs, as indicated. A full array of images obtained for the co-
transfections can be seen in Fig. S7 and equivalent transmitted light images are shown in Fig. S8. Scale bar bottom right indicates 100 m. C, substitution
mutations of the DTRL PDZ-binding motif are associated with significantly lower levels of fluorescence within iBox-PAK4cat crystals (two-way ANOVA with
Sidak’s multiple comparisons test, F(4, 122) 287, p 0.0001). Each point represents the mean fluorescence intensity of a single image containing multiple
crystals, as shown in Fig. S9. n 10 –15.
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structured extensions are common to several members of the
NHERF family (Fig. 3B, Fig. S2). Indeed, bioinformatics studies
have suggested that 40% of PDZ domains contain structured
extensions outside of the core PDZ-fold (34). One of the best
characterized examples to date is the third PDZ domain of
PSD-95, which also contains a C-terminal 3 helix. The overall
characteristics of this C-terminal extension are very similar to
the extended region of NHERF1 PDZ2 in that (i) the extension
is distal to the binding site, (ii) the extension does not induce
any major structural changes, and (iii) the extension increases
binding affinity for the ligand 21-fold (35). As such, extension
mediated allosteric stabilization of the binding site may be a
commonmechanism shared among several PDZ domains. Fur-
ther structural and biochemical studies are required to further
elucidate the role of these structured extensions across the
NHERF family.
This study has also provided further insight into the deter-
minants of interaction between NHERF1 PDZ2 and the CFTR
PDZ-binding motif. Although previous studies had suggested
that the Glu43 to Asp183 substitution in PDZ2 was the sole
determinant for the reduced binding affinity of NHERF1 PDZ2
to the CFTR C terminus relative to PDZ1 (17, 33), the crystal
structure presented here demonstrates that Asp183 is able to
maintain the interactionwithR-1 (Fig. 2A). These findingswere
confirmed by MD simulations, where this salt bridge interac-
tion is found to be steady for the entire production (Fig. 6),
indicating that the higher binding affinity achieved byNHERF1
PDZ1 is likely to be a result of a variety of structural features
throughout the binding pocket, rather than sequence variation
of a single residue. Interestingly, the MD simulations indicated
two distinct binding modes for R-1 and L0 within the binding
pocket. In addition to the canonical interaction between L0 and
the carboxylate-binding loop, L0 can also be observed to shift
toward Arg220, with a water molecule instead facilitating the
indirect interaction between the carboxylate group and
theGYGFmotif.Water-mediated hydrogen bonds between the
terminal residue of the binding motif and the PDZ-binding
pocket have been reported previously (28, 36), although the
mode observed here appears to be mechanistically distinct.
This orientation of L0 is also associated with the formation of a
hydrogen bond between the R-1 side chain with the backbone
carbonyl of Ser162, a finding that is consistent with previous
reports that phosphorylation of Ser162 disrupts the interaction
between NHERF1 PDZ2 and the PDZ-binding motif of CFTR
(15).
The novel iBox-PAK4cat protein-protein interaction assay
presented here has provided further insight into the determi-
nants of the interaction between NHERF1 and CFTR. This
approach allows clear differentiation between PDZ do-
main-binding (iBox-PAK4cat-DTRL) and nonbinding (iBox-
PAK4cat-AAAA) motifs through visual comparison of crystal
fluorescence (Fig. 4B). Introduction of the C-terminal leucine
to alanine substitution mutant (iBox-PAK4cat-DTRA) had a
drastic effect on GFP integration into the crystals, with crystal
Figure 6. Bindingmodes observed for L0 and R-1 inmolecular dynamics simulations. The two binding modes shown correspond to a 50:50 distribution
between the two states. Representative frames of two binding modes were selected after clustering of two MD simulations. NHERF1 PDZ2 is colored in cyan
and the CFTR PDZ-binding motif in beige. Black dashes represent bond distances measuring 3.3 Å or less. For clarity, hydrogens are shown for the water
molecule only.
Table 2
Binding free energies for WT and alanine mutants with MMPBSA and SIE methods
G kcal/mol G kcal/mol G kcal/mol G kcal/mol G kcal/mol
( S.E.) DTRL ( S.E.) ATRL ( S.E.) DARL ( S.E.) DTAL ( S.E.) DTRA
MM-PBSA 73.24 0.37 63.17 0.34 72.66 0.35 51.37 0.52 72.46 0.40
75.51 0.40 64.55 0.30 74.72 0.38 58.28 0.33 73.69 0.34
SIE 14.53 0.05 10.88 0.03 11.33 0.03 10.46 0.04 11.27 0.03
15.08 0.03 10.93 0.02 11.51 0.03 10.36 0.02 11.43 0.03
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fluorescence levels appearing similar to the iBox-PAK4cat-
AAAAnegative control (Fig. 5B). Such a finding is supported by
co-immunoprecipitation data (37) and is consistent with the
finding that the binding pocket is stereochemically adapted for
the accommodation of the leucine side chain (Fig. 2B). As such,
it is likely that the much smaller side chain of alanine would
produce a much less energetically favorable interaction. The
phosphomimetic motif-containing iBox-PAK4cat-DERL con-
struct was also found to result in reduced fluorescence levels
(Fig. 5C). Phosphorylation of the serine or threonine residues at
this position has been demonstrated to disrupt the PDZ
domain-motif interaction in several other cases (38–40).
Although phosphorylation of this residue in CFTR has been
hypothesized previously (15), the role of phosphorylation as a
regulatory mechanism for this interaction requires further
investigation.
Quantitative analysis of iBox-PAK4Cat-ATRL, iBox-
PAK4Cat-DARL, and iBox-PAK4cat-DTAL constructs indi-
cated that these PDZ-binding motif mutants had significantly
lower levels ofGFP integration into iBox-PAK4cat crystals than
the WT CFTR PDZ-binding motif (Fig. 5C). This supports the
finding, as demonstrated by the crystal structure (Fig. 2A), that
interactions within the binding pocket enable the specific rec-
ognition of the aspartate, threonine, and arginine residues of
the CFTR PDZ-binding motif. These findings were corrobo-
rated byMD and binding free energy studies, where the alanine
substitution mutants were found to be less energetically favor-
able than the WT-binding motif. Interestingly, ATRL and
DTAL sequences correspond to the PDZ-binding motifs of the
sodium-dependent phosphate co-transporter and the H-
ATPase, respectively, both of which have been shown to bind to
the PDZ domains of NHERF1 (33, 41–43). As such, the PDZ-
binding motif of CFTR appears to be an optimal PDZ-binding
motif for interaction with the PDZ domains of NHERF1. This
indicates that whereas the consensus motif X-S/T-X- repre-
sents theminimal requirements for interactionwith type I PDZ
domains, residue selection at P-1 and P-3 does appear to influ-
ence the affinity of the interaction. There are several instances
where competition between different PDZ domain-containing
proteins has been shown to play a role in dynamic regulation of
cell signaling (10, 13, 44, 46). As such, the ability of PDZ
domains to bind to both optimal and suboptimal motifs may be
key tomaintaining promiscuity of the PDZdomain-motif inter-
action, whereas also allowing certain interactions to take prec-
edence over others in the context of the PDZ domain interac-
tion network.
Although the assay in its current state is best described as
semi-quantitative, the results presented here provide proof-of-
principle that iBox-PAK4cat crystals represent a potentially
useful tool for the study of PDZ domain-motif interactions in a
cellular context. The advantages of the iBox-PAK4cat system
for detecting PDZ-motifs are clear: the assay is in cellulo,
robust, quick, with the simple readout of fluorescence, and thus
is a simple assay to introduce into a cell biology laboratory. We
have demonstrated here that two PDZ domains can be easily
screened against a number of interacting motifs. This strategy
could easily be adapted to a high-throughput format allowing
for multiple PDZ domains to be screened against multiple
interactionmotifs. Indeed, this assay could be adapted to probe
other protein-protein interactions, provided that both interac-




For the generation of NHERF1 PDZ2-DTRL, cDNA for
human NHERF1 PDZ2 (NHERF1 residues 150–270) was
cloned into pSY5 vector (47) using standard ligation-indepen-
dent cloning methods (48). The CFTR PDZ-binding motif
(CFTR residues 1477–1480) was inserted downstream using a
QuikChange II Site-directedMutagenesis Kit (Agilent) accord-
ing to the manufacturer’s instructions. For the generation of
iBox-PAK4cat-DTRL, iBox-PAK4cat-ATRL, iBox-PAK4cat-
DARL, iBox-PAK4cat-DTAL, iBox-PAK4cat-DTRA, iBox-
PAK4cat-DERL, and iBox-PAK4cat-AAAA constructs, the rel-
evant tetrapeptide motifs were inserted into iBox-PAK4cat
within the pXJ40 vector (1) using the QuikChange II Site-di-
rected Mutagenesis Kit (Agilent) according to the manufactu-
rer’s instructions. For the generation of GFP-PDZ1 and GFP-
PDZ2 constructs, NHERF1 PDZ1 (NHERF1 residues 11–120)
and PDZ2 (NHERF1 residues 150–270) domains were inserted
into themultiple cloning site of pXJ40-GFP (49) usingXhoI and
KpnI restriction sites according to standard PCR restriction
cloning methods. In all cases the presence of the desired con-
struct was confirmed through sequencing.
Expression, purification, and crystallization of PDZ2-DTRL
NHERF1 PDZ2-DTRL was expressed in Escherichia coli
BL21 (DE3) (New England BioLabs). Cultures in autoinduction
media (12 g/liter of tryptone, 24 g/liter of yeast extract, 9.4
g/liter of K2HPO4, 2.2 g/liter of KH2PO4, 8 ml/liter of glycerol,
50 mMNH4Cl, 20 mMMgSO4, 5 mMNa2SO4, 0.3% (w/v) -lac-
tose, 0.015% (w/v) D-glucose) were grown at 37 °C until an
OD600 of 0.6–0.8, following which they were grown overnight
at 15 °C. Cultureswere harvested by centrifugation and pelleted
cells were resuspended in 50 mM TrisHCl, pH 8.0, 500 mM
NaCl, and 20 mM imidazole. Cells were lysed using sonication
and the cell lysatewas clarified through centrifugation.All puri-
fication steps were carried out using the ÅKTA Express Purifi-
cation System (GE Healthcare). Lysates were loaded onto a
5-ml HisTrap FF nickel-nitrilotriacetic acid column (GE
Healthcare). The columnwas washed with 50mMTrisHCl, pH
8.0, 500 mM NaCl, and 20 mM imidazole prior to elution of
boundproteinswith 50mMTrisHCl, pH8.0, 500mMNaCl, and
250 mM imidazole. The eluted material was collected and
exchanged into 50 mM TrisHCl, pH 8.0, on a HiPrep 26/10
desalting column (GEHealthcare). Eluted proteins were loaded
onto a 1-ml HiTrap Q HP column (GE healthcare) for anion-
exchange chromatography. Bound proteins were eluted using a
gradient of 0–500mMNaCl, followed by a final elutionwith 1 M
NaCl. Eluted fractions were analyzed using SDS-PAGE. Rele-
vant fractions were combined and further purified by size-ex-
clusion chromatography in 50 mM TrisHCl, pH 8.0, 150 mM
NaCl using a HiLoad 16/600 Superdex 75 column (GE Health-
care). The protein eluted as a single peak and eluted fractions
were analyzed using SDS-PAGE and Coomassie Brilliant Blue
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staining. Fractions of sufficient purity were combined and con-
centrated in a 10-kDa molecular mass cut-off concentrator.
Protein concentration was determined using the Pierce bicin-
choninic acid protein assay kit (ThermoScientific) according to
the manufacturer’s instructions. Crystallization was carried by
mixing 2 l of 10.5 mg/ml of protein solution with 1 l of 1.65
M ammonium sulfate and 100 mM trisodium citrate, pH 5.6,
using the hanging drop diffusion method. Bipyramidal-shaped
crystals grew at 15 °C, taking approximately onemonth to grow
to full size at which point they measured 50 m at their widest
dimension.
X-ray data collection and structure determination
Crystals were harvested into mother liquor containing 30%
(v/v) glycerol and flash-frozen in liquid nitrogen. X-ray diffrac-
tion data for NHERF1 PDZ2-DTRL were collected remotely at
the Australian Synchrotron. Data were collected using an
ADSC Quantum 315r CCD detector at the MX2 beamline at a
wavelength of 1.0 Å. Each image covered an oscillation of 0.5
degrees. Images were indexed and integrated using MOSFLM
(50). The space group was determined to be I212121 using
POINTLESS and the data were scaled using AIMLESS, both
within the CCP4 suite of programs (51). The structure was
solved by molecular replacement in PHASER (52) using the
structure of NHERF1 PDZ2 bound to the CXCR2 PDZ-binding
motif (PDB 4Q3H) as a search model. The solvent content was
determined to be 50.1% with a Matthews coefficient (Vm) of
2.50 Å3/Da. This is consistent with the presence of two com-
plexes within the asymmetric unit. Manual building of the
extended PDZ domain and PDZ-binding motif was carried out
in Coot molecular graphics software (53). The structure was
refined to a resolution of 2.20 Å using phenix.refine (54), yield-
ing a final Rwork/Rfree of 0.2360/0.2752. In the final round of
refinement a twinning correction was applied (-h,-k,-l), which
resulted in a 4% drop in the Rfree value. All figures depicting the
structure were generated in PyMOL (55), unless otherwise
stated.
Transfection of cell culture
Monkey COS-7 cells were grown in high-glucose Dulbecco’s
modified Eagle’s medium (HyClone) supplemented with 10%
(v/v) bovine calf serum (HyClone). Cells were incubated at
37 °C with 5%CO2. Transfections were carried out using jetPEI
transfection reagent (Polyplus transfection) according to the
manufacturer’s instructions.
Live cell imaging of crystal growth
Relevant constructs were co-transfected into COS-7 cells in
24-well black-walled glass-bottomed -plate (Ibidi). Immedi-
ately after transfection, images were acquired on an Eclipse Ti
inverted microscope (Nikon) using a 10 	 0.3 SPlan Fluar
objective, the filter sets for GFP, and a pE-300 LED (CoolLED)
fluorescent light source. Imaging software NIS Elements
AR.46.00.0.point visiting was used to allow five positions to be
imaged for each well within the same time course. Images were
collected using a CoolSnap Monochrome camera (Photomet-
rics) every 30min for a total of 71.5 h. GFP fluorescence images
were acquired using a fixed exposure time of 200ms. Transmit-
ted light imageswere acquired using a fixed exposure time of 50
ms. Cells weremaintained at 37 °C and 5%CO2 throughout the
course of the experiment.
Cell breakage and separation of iBox-PAK4cat crystals
Relevant constructs were co-transfected into COS-7 cells in
6-well dishes. Three days post-transfection, Dulbecco’s modi-
fied Eagle’s medium was aspirated from the cells and 500 l of
hypotonic lysis buffer (50 mM TrisHCl, pH 7.4, 25 units/ml of
DNase I (Promega), 0.2% (v/v) TritonX-100) was added to each
well. Plates were rocked at ambient temperature until cells
could be observed to detach from the plate. Lysed cells were
centrifuged in a square-bottomed cuvette at ambient tempera-
ture for 5min at 200	 g in a bench-top centrifuge, such that the
pellet contained cell debris and the supernatant contained crys-
tals. Supernatants were aspirated into a black-walled glass-bot-
tomed 24-well plate (Ibidi) for imaging.
Crystal imaging and quantification of GFP fluorescence
Harvested crystals were imaged in 24-well black-walled
glass-bottomed-plate (Ibidi) on anMMICellCut lasermicro-
dissection system (Olympus) using a 10	 0.3UPlan FLNobjec-
tive, the filter sets for FITC, and a xenon mercury fluorescent
light source. Images were collected using an Orca ER C4742-
95-12ERG monochrome camera (Hamamatsu) using a fixed
exposure time of 100 ms. Fluorescence intensity quantification
was carried out using Fiji software (56). Crystal-containing
regions were selected using automatic thresholding with the
Otsu algorithm and the mean gray value was measured. The
acquired values were plotted and subjected to two-way
ANOVA with Sidak’s multiple comparisons test using
GraphPad Prism 7.0 software.
Multiple sequence alignments
Multiple sequence alignment was carried out with Clust-
alW2 using the default settings (57).
Models building and molecular dynamics simulations
The initial NHERF1 PDZ2-DTRL complex was edited to
consider only the sequence portion interacting with the
NHERF1 PDZ2 core domain. Subsequently the DTRL portion
of the WT peptide was modified to obtain the corresponding
alanine mutants (ATRL, DARL, DTAL, and DTRA). The sys-
tems were modeled using the Protein Preparation Wizard tool
(58) of the Schrödinger Suite and the protonation states of
His169 and His212 were evaluated and verified using the PropKa
routine at pH 7.0  0.2 as default. Although on initial evalua-
tion both histidines were estimated to be in HID form (neutral,
-nitrogen protonated), on further analysis with the PropKa
routine, His212 was estimated to be in the HIE state (neutral,
	-nitrogen protonated) with a pKa of 5.20, whereas His169 was
evaluated to be present in the HIP state (1 charged, both -
and 	-nitrogens protonated) with a pKa value of 7.13. As a con-
sequence, four combinations of protonation states for His169
(HID/HIP) and His212 (HID/HIE) of NHERF1 PDZ2 were eval-
uated. For each combination, two replicate 50-ns production
runs were performed and evaluated to assess the persistence of
the pKa values obtained during initial settings. Frames at
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defined time steps (every 5–10 ns) were selected and evaluated.
All the investigated frames of WT simulations reporting
HIP169 demonstrated awell-maintainedHIP state as predicted
in earlier phases. The RMSDof the C atomswas evaluated for:
1) the whole complex, 2) the secondary structure of the PDZ2
domain, and 3) the CFTR PDZ-binding motif (Fig. S10). Gen-
erally, the RMSD value of the C atoms in the secondary struc-
ture was found to remain below 1.0 Å in all of the systems.
Nevertheless, an improved stabilization of the peptide was
observed for simulations reporting the HIP state for His169. In
particular, for the HIP169/HID212 state, the RMSD value
related to the C atoms was found to oscillate between 1.0 and
3.0 Å and the calculated binding free energies with both MM-
PBSA and the SIEmethods indicated that this systemhadmuch
higher stability than the other systems. As such, our analyses
focused on the HIP169/HID212 replicas. For simulations
employing the DARL, DTAL, and DTRA alanine substitution
mutants, the same protonation states as described for the WT
complex were employed. However, for the ATRL alanine sub-
stitutionmutant, the absence of aspartate at the P-3 of the bind-
ing motif was found to significantly change the local environ-
ment so that the pKa value of His169 was decreased. As a result,
for this system only the 	 nitrogen of His169 was considered to
be protonated. This procedure has been repeated to verify the
pKa at fixed time steps during all simulations. MD simulations
were carried out using the AMBER package, version 14 (59). All
complexes were placed in a rectangular parallel piped water-
box and solvated with a 25 Å water cap, employing the TIP3P
explicit solvent model and different counterions to neutralize
the systems. Simulationswere conducted using the ff14SB force
field at 300 K, the particle mesh Ewald method for long-range
electrostatic interactions, and periodic boundary conditions. A
cut-off of 10 Å for the nonbonded interactions was also
included and the general time step for all simulations was set as
2.0 fs. The SHAKE algorithm was applied to keep all bonds
involving hydrogen atoms rigid. Prior to the simulations, each
system was subjected to an energy minimization using the
steepest descent algorithm, followed by conjugate gradient.
The temperatures of the systems were raised from 0 to 300 K
within 500 ps of simulation time under constant-volume peri-
odic boundary condition. During both stages, all C atoms of
the complexes were kept restrained with a harmonic force con-
stant of 10 kcal/molÅ2. Multiple equilibration stages were
lately performed with a constant-pressure periodic boundary
condition and a gradual decrease of the harmonic force con-
stant, until the whole system was completely relaxed. During
this stage (equivalent to 3–5 ns), the pressure and the temper-
ature of the systems were kept constant by employing the
Monte Carlo barostat (with anisotropic pressure scaling) and
the Langevin thermostat. Molecular dynamics productions
were finally carried out with the same temperature and pres-
sure conditions but without restraints for a singular amount of
50 ns for each peptide-protein complex. The CPPTRAJ and
PTRAJ modules of AmberTools were employed to process and
analyze all trajectories, whereas UCSF Chimera (60) was uti-
lized for visualization and preliminary inspections. RMSDplots
and all images were generated using, respectively, Gnuplot and
PyMOL (55).
Binding free energy studies
Binding energy studieswere carried out by applying theMM-
PBSA (61–63) method as general standard and SIE method
(11–14) in line with an approach employed previously (15). For
the calculation of binding energies using the MM-PBSA
method (61–63), the MM-PBSA implementation of the
AMBER 14 package was used (59). The Van derWaals, electro-
statics, and internal interaction were estimated by employing
the SANDER module, whereas the MM-PBSA module was
used to calculate polar energies. Dielectric constants of 1 and 80
were applied to represent the gas and water phases, respec-
tively.MOLSURFwas employed to estimate the nonpolar ener-
gies, whereas the entropic term was deemed as approximately
constant compared with the systems interactions. For the cal-
culation of binding energies using the SIE method, an adapted
version of the SIETRAJ tool (available at RRID:SCR_018021)
was used. The SIETRAJ tool employed several scripts based on
a Tcl runtime library (BRIMM) and its internal Poisson solver
and surface generation methods (45, 64, 65).
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Atomic coordinates and structure factor files have been
deposited in the Protein Data Bank under accession code
6RQR.
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